Levodopa (administration & dosage) < Levodopa (adverse effects) < Levodopa (antagonists & inhibitors)

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 123.
[20-40] [0 - 20][0 - 50][40-60]

Ident.	Authors (with country if any)	Title
000197 (2001)	F. Maurel [France] ; H. Lilliu ; C. Le Pen	[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
000199 (2000)		Pergolide and Parkinson's disease: new preparation. No clear benefit.
000200 (2001)	O. Rascol [France] ; I. Arnulf ; H. Peyro-Saint Paul ; C. Brefel-Courbon ; M. Vidailhet ; C. Thalamas ; A M Bonnet ; S. Descombes ; B. Bejjani ; N. Fabre ; J L Montastruc ; Yves Agid [France]	Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.
000202 (2001)	E. Bezard [France] ; J M Brotchie ; C E Gross	Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
000239 (2002)	Paul Krack [France] ; Valérie Fraix ; Alexandre Mendes ; Alim-Louis Benabid ; Pierre Pollak	Postoperative management of subthalamic nucleus stimulation for Parkinson's disease.
000248 (2002)	I. Ghorayeb ; F. Yekhlef ; V. Chrysostome ; E. Balestre ; B. Bioulac ; F. Tison	Sleep disorders and their determinants in multiple system atrophy
000252 (2002)	P. Krystkowiak [France] ; L. Defebvre	[Rush dyskinesia scale or Goetz scale].
000283 (2002)	Elena Moro [France] ; Rianne J A. Esselink ; Alim Louis Benabid ; Pierre Pollak	Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.
000301 (2002)	E. Lagrange [France] ; P. Krack ; E. Moro ; C. Ardouin ; N. Van Blercom ; S. Chabardes ; A L Benabid ; P. Pollak	Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD.
000320 (2003)	Marc Ziegler [France] ; Alexandre Castro-Caldas ; Susanna Del Signore ; Olivier Rascol	Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
000323 (2002)	O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc	[Management of levodopa-induced dyskinesia].
000347 (2003)	Olivier Rascol [France]	Monoamine oxidase inhibitors--is it time to up the TEMPO?
000359 (2003)	Julie Hudry [France] ; Stéphane Thobois ; Emmanuel Broussolle ; Patrice Adeleine ; Jean-Pierre Royet	Evidence for deficiencies in perceptual and semantic olfactory processes in Parkinson's disease.
000366 (2003)		Entacapone/levodopa/carbidopa combination tablet: Stalevo.
000404 (2003)	Bechir Jarraya [France] ; Anne-Marie Bonnet ; Charles Duyckaerts ; Jean-Luc Houeto ; Philippe Cornu ; Jean-Jacques Hauw ; Yves Agid [France]	Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study.
000418 (2004)	F. Durif [France] ; B. Debilly ; M. Galitzky ; D. Morand ; F. Viallet ; M. Borg ; S. Thobois ; E. Broussolle ; O. Rascol	Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.
000421 (2004)	Frédéric Macia [France] ; Caroline Perlemoine ; Irène Coman ; Dominique Guehl ; Pierre Burbaud ; Emmanuel Cuny ; Henri Gin ; Vincent Rigalleau ; François Tison	Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight.
000434 (2004)	P. Pollak ; F. Tison ; O. Rascol ; A. Destee ; J. Pere ; J. Senard ; F. Durif ; I. Bourdeix	Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up
000452 (????)	Luc Defebvre [France]	[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation].
000466 (2005)	Stéphane Chapuis [France] ; Lemlih Ouchchane ; Olivier Metz ; Laurent Gerbaud ; Franck Durif	Impact of the motor complications of Parkinson's disease on the quality of life.
000480 (2004)	M. Bouhaddi [France] ; F. Vuillier ; J O Fortrat ; S. Cappelle ; M T Henriet ; L. Rumbach ; J. Regnard	Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Levodopa (adverse effects)" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Levodopa (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Levodopa (adverse effects)
}}

---

This area was generated with Dilib version V0.6.29. Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024